Liflex raises $5.25M Series A for anti-aging RNA therapies
What's the deal? Liflex ScienceDealroom has a profile for this one. Try Dealroom →, a South Korean biotech developing RNA treatments for age-related disease, has raised US$5.87M in a Series A round. It closed the round on November 10, the company said.
Who's backing it? Investors include Korea Development BankDealroom has a profile for this one. Try Dealroom →, Medytox Venture InvestmentDealroom has a profile for this one. Try Dealroom →, Murex PartnersDealroom has a profile for this one. Try Dealroom →, Future Science Technology Holdings, Myriad PartnersDealroom has a profile for this one. Try Dealroom →, Quad Asset ManagementDealroom has a profile for this one. Try Dealroom →, and Korea Science and Technology HoldingsDealroom has a profile for this one. Try Dealroom →. The mix pairs state-linked institutions with private firms.
What's the endgame? Founded by Seoul National University professor Kim Jin-hong, Liflex builds therapies on a microRNA degradation platform. Its lead candidate, a preclinical RNA treatment for osteoarthritis, is targeted to enter clinical trials in the second half of 2027.
Proceeds will fund trial preparation for that candidate and the development of three follow-on programs targeting obesity, kidney disease, and heart disease, all built on the same platform.
Why now? The company is building on research momentum. In October, teams led by Kim and co-founder Kim Yi-jun of Ewha Womans University published findings in Cell Metabolism and Trends in Biotechnology , the latter involving a Harvard Medical School team. Liflex is exploring programmable genetic circuits as a potential second core platform.
What could go wrong? This is a development bet, not validation. The lead candidate is preclinical, and the obesity, kidney, and heart programs sit at an even earlier stage.
The signal: South Korean biotech funding rose 53.6% year on year in the first half of 2026, but capital is increasingly favouring companies with clinical evidence or a clear path to an IPO. A substantial early-stage raise in that more selective market — backed by both public and private money — signals continued appetite for platform-driven drug discovery.
Read more: wowtale.net
Image credit: NavyMedicine